+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 70Years
All Genders
ID07540897

Randomized, Double-Blind Study Evaluating ALKS 2680 Tablets for Treating Narcolepsy Type 1 in Adults

Led by Alkermes, Inc. · Updated on 2026-10-07

150

Participants Needed

20

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the effects of ALKS 2680 tablets on adults with Narcolepsy Type 1 NT1. The study aims to measure reductions in daytime sleepiness, cataplexy sudden loss of muscle tone, and overall disease symptoms. This is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of ALKS 2680 compared with placebo. Participants will be randomly assigned to receive one of two doses of ALKS 2680 tablets or placebo tablets. All treatments are taken orally once daily for 12 weeks. The study employs a parallel design with triple masking to compare the effects of the two doses of ALKS 2680 against placebo over the treatment period. During the 12-week treatment, participants will undergo various assessments including the Maintenance of Wakefulness Test to measure sleep latency, Epworth Sleepiness Scale, cataplexy rate tracking, and cognitive and fatigue questionnaires. Researchers will also monitor treatment-emergent adverse events up to two weeks after treatment ends. The total participation duration includes treatment and follow-up assessments to evaluate treatment impact and safety.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

Research Team

D

Director, Clinical Trial Manager

D

Director, Clinical Trial Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here